Recent advancement in pharmacological effects of artemisinin and its derivatives

Abstract

Abstract: Artemisinin, an active compound extracted from Artemisia annua, L.together with its derivatives are widely used as anti-malarial drugs.In recent years, artemisinin and many of its analogs were reported to possess some other effects such as anti-inflammatory, immuno-modulation and antitumor activities besides antiparasitic actions against Plasmodium falciparum and Schistosoma.Based on an introduction of the conventional actions and mechanisms of these drugs, we reviewed the recent progress of their new biological actions in this article.

Key words: artemisinin, anti-malarial, anti-tumor, sepsis, antiparasitic

CLC Number:

R969
R285.6

GUO Yan, WANG Jun, CHEN Zheng-tang. Recent advancement in pharmacological effects of artemisinin and its derivatives[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 615-620.

References

1 Li Y, Wu YL.An over four millennium story behind qinghaosu (artemisinin)-a fantastic antimalarial drug from a traditional Chinese herb[J].Curr Med Chem, 2003;10:2197-223
2 Pandey AV, Tekwani BL, Singh RL, Chauhan VS.Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite [J].J Biol Chem, 1999;274:19383-8
3 Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG.An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials[J].Biochem Pharmacol, 1998;55:727-36
4 Zhang F, Gosser DK Jr, Meshnick SR.Hemin-catalyzed decomposition of artemisinin (qinghaosu)[J].Biochem Pharmacol, 1992;43:1805-9
5 Hoppe HC, van Schalkwyk DA, Wiehart UI, Meredith SA, Egan J, Weber BW.Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum[J].Antimicrob Agents Chemother, 2004;48:2370-8
6 Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, et al.Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation [J].FEBS Lett, 2003;552:141-4
7 Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al.Artemisinins target the SERCA of Plasmodium falciparum[J].Nature, 2003;424:957-96
8 Ridley RG.To kill a parasite[J].Nature, 2003;424:887-9
9 Efferth T, Olbrich A, Bauer R.mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether [J].Biochem Pharmacol, 2002;64:617-23
10 Beekman AC, Wierenga PK, Woerdenbag HJ, Van Uden W, Pras N, Konings AW, et al.Artemisinin-derived sesquiterpene lactones as potential antitumour compounds:cytotoxic action against bone marrow and tumour cells[J].Planta Med, 1998; 64:615-9
11 林芳, 钱之玉, 薛红卫, 丁健, 林莉萍.青蒿素和青蒿琥酯对人乳腺癌MCF-7 细胞的体外抑制作用比较研究[J].中草药, 2003;34:347-9
12 Chen HH, Zhou HJ, Fang X.Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro [J].Pharmacol Res, 2003;48:231-6
13 Yamachika E, Habte T, Oda D.Artemisinin:an alternative treatment for oral squamous cell carcinoma [J].Anticancer Res, 2004;24:2153-60
14 Singh NP, Lai HC.Artemisinin induces apoptosis in human cancer cells[J].Anticancer Res, 2004;24:2277-80
15 Efferth T, Oesch F.Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines[J].Biochem Pharmacol, 2004;68:3-10
16 Disbrow GL, Baege AC, Kierpiec KA, Yuan H, Centeno JA, Thibodeaux CA, et al.Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo[J]. Cancer Res, 2005;65:10854-61
17 Sadava D, Phillips T, Lin C, Kane SE.Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells[J].Cancer Lett, 2002;179:151-6
18 Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, et al.Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron[J].Free Radic Biol Med, 2004;37:998-1009
19 McCarty MF.Turning an'Achilles'Heel'into an asset-activation of HIF-1alpha during angiostatic therapy will increase tumor sensitivity to iron-catalyzed oxidative damage[J].Med Hypotheses, 2003;61:509-11
20 Lai H, Sasakit, Singh NP.Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds[J]. Expert Opin Ther Targets, 2005;9:995-1007
21 Wartenberg M, Wolf S, Budde P, Grunheck F, Acker H, Hescheler J, et al.The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies[J].Lab Invest, 2003;83:1647-55
22 Chen HH, Zhou HJ, Fang X.Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro[J].Pharmacol Res, 2003;48:231-6
23 Kim SJ, Kim MS, Lee JW, Lee CH, Yoo H, Shin SH, et al. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro[J].J Cancer Res Clin Oncol, 2006;132:129-35
24 Singh NP, Lai HC.Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells[J].Anticancer Res, 2005;25:4325-31
25 梁爱华, 薛宝云, 李春英, 王金华, 王岚.青蒿琥酯对内毒素诱导的一氧化氮合成的抑制作用[J].国外医学中医中药分册, 2001;23:156-8
26 谭余庆, 赵一.青蒿提取物抗内毒素实验研究[J].中国中药杂志, 1999;24:166-71
27 王俊, 周红.青蒿素对CpG DNA 攻击小鼠保护作用的实验研究[J].中国临床药理学与治疗学, 2005;10:290-3
28 刘玮, 周红, 丁国富, 鲁永铃, 王良喜, 罗平.小剂量CpG ODN 预处理对细菌脓毒症小鼠的保护作用及其机制探讨[J].中国临床药理学与治疗学, 2005;10:314-7
29 He H, Kogut MH.Cpg-ODN-induced nitric oxide production is mediated through clathrin-dependent endocytosis, endosomal maturation, and activation of PKC, MEK1/2 and p38 MAPK, and NF-kappaB pathways in avian macrophage cells[J].Cell Signal, 2003;15:911-7
30 Xiao SH.Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins[J]. Acta Trop, 2005;96:153-67
31 Utzinger J, Xiao S, N'Goran EK, Bergquist R, Tanner M. The potential of artemether for the control of schistosomiasis[J]. Int J Parasitol, 2001;31:1549-62
32 廖琳, 刘佩娜, 陈静科, 陈静先, 马莹.双氢青蒿素对阴道毛滴虫作用的体外试验研究[J].四川大学学报,2005;36:140-1
33 李文桂, 陈雅棠, 刘成伟, 余登高.双氢青蒿素治疗大鼠卡氏肺孢子虫肺炎后的肺脏病理变化观察[J].动物医学进展, 2004;25:94-7

[1]	XING Bomin, GUO Na, NING Haihui, DING Xinyun, MA Yuqing. Effects of Rho kinase inhibitors on septic liver injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 544-550.
[2]	CHEN Yugang, TU Yanqiong, WANG Congqing, CHEN Juan, ZHANG Bohong. Network pharmacology and molecular docking to discuss the mechanism of Jinhutongdan prescription in the treatment of cholelithiasis and experimental verification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1090-1098.
[3]	HE Rui, TENG Wenbin, YAO Liuxu, SHAN Yue, ZHU Shengmei, LI Yuhong. Protective effect of hypoxia inducible factor-1α on intestinal mucosal barrier in sepsis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 264-270.
[4]	LI Hui, LI Jun, HUAN Suqin, LI Yuhong, FAN Jun. Protection effect of dexmedetomidine against sepsis-induced intestinal mucosal barrier injury by up-regulating hypoxia inducible factor-1ɑ in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1386-1392.
[5]	YANG Huifang, LUO Ying, ZHAO Li. Effects of dexmedetomidine on renal function and serum inflammatory factors in sepsis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 857-861.
[6]	RU Caiwang, YUAN Tianming, YANG Bingfen, WU Fugen, LIN Yingrong, MO Miaojun. Effects of imipenem-cilastatin sodium combined with immunoglobulin on serum PCT, hs-CRP and TNF-α in children with baby sepsis complicated with disseminated intravascular coagulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 559-565.
[7]	TIAN Dahao, LU Linming, ZHI Hui, ZHOU Jue, WANG Xiaoqing, JIANG Yuhua. AHVAC-I inhibits the proliferation in human primary gastric cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 505-511.
[8]	XUE Hua, LU Lili, XIANG Hui, QIAN Zhenhua. Curative efficacy of ulinastatin combined with hydrocortisone in treatment of severe sepsis secondary shock and effects on serum factor levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 313-317.
[9]	QIAO Yang, CHEN Qun, YANG Guang,CAO Yingya, LU Weihua. iTRAQ technology based differences of protein expression in sepsis-associated encephalopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1269-1274.
[10]	CAI Yun, XU Jinlong, ZHANG Mao. Pharmacokinetic of piperacillin/tazobactam in patients with sepsis during continuous venovenous hemodiafiltration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 905-911.
[11]	WEI Liuping, WU Qing, YIN Nange, YANG Bin, MAO Jinxiao. Effect and safety of lactoferrin for prevention of late-onset sepsis in premature neonates: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 653-660.
[12]	FANG Jingjing, TAO Jing, HUANG Qin, SHI Chaolu, YAN Biqing, GAI Lei, LI Xuguang. Effects of platelet activation on renal tubular epithelial cells in sepsis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 283-289.
[13]	YANG Yong, DENG Xianghui, HE Runzhi, HUANG Jia. Effects of hydrocortisone sodium succinate continuous intravenous infusion in the treatment of severe septic shock [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1297-1301.
[14]	WU Yonglei, WANG Dan, ZHANG Suiyang, WANG Ying, SUN Qin. Pharmacokinetics and pharmacodynamics of meropene administered by traditional prolonged infusion or optimized prolonged infusion in different tissues of septic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 767-774.
[15]	WANG Jian，ZHANG Wen. Correlation and clinical value of PCT, SVRI, SOFA in sepsis patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 443-447.